{Reference Type}: Journal Article
{Title}: ALINA: Another stepping stone toward a future of LDCT lung cancer screening in never-smokers?
{Author}: Nagasaka M;Ly CT;Ou SI;
{Journal}: Med
{Volume}: 5
{Issue}: 7
{Year}: 2024 Jul 12
暂无{DOI}: 10.1016/j.medj.2024.05.010
{Abstract}: The ALINA trial1 demonstrated that 2 years of adjuvant alectinib achieved statistically significantly improved 2-year overall and central nervous system (CNS) disease-free survival over platinum-doublet chemotherapy in resected early-stage (IB ≥ 4 cm to IIIA) ALK+ non-small cell lung cancer (NSCLC). Identifying early-stage ALK+ NSCLC patients (60% were never-smokers in the ALINA trial) may require low-dose computed tomography (LDCT) lung cancer screening in never-smokers.